title: Recurrence of hepatitis C infection: Where are we now?
abstract: 1. Hepatitis C-associated liver failure is the most common indication for liver transplantation, and approximately 10% of HCV-infected recipients will die or lose their allograft secondary to recurrent HCV infection. 2. Risk factors associated with histological recurrence of HCV include donor (age, fat content, ischemic time, and living donor), recipient (age and non-Caucasian race), clinical (rejection and CMV), and viral (viral load and quasispecies). 3. Treatment of recipients with histological recurrence is with pegylated IFN (+/- ribavirin). The role of hepatitis C immunoglobulin in the management of postransplant HCV is still evolving. (
authors.affiliation: Department of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA. charlton.michael@mayo.edu
authors.forename: Michael
authors.initials: M
authors.lastname: Charlton
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use; D006526:Hepatitis C / Q000150:complications*; D006801:Humans; D017093:Liver Failure / Q000209:etiology / Q000601:surgery*; D016031:Liver Transplantation; D012307:Risk Factors; D055502:Secondary Prevention
chemical_list: D000998:Antiviral Agents